Ocular involvement in patients with posttransplant lymphoproliferative disorder

Archives of Ophthalmology

Volumn 119, Issue 2, 2001, Pages 183-189

  Cho, A S ^a   Holland, G N ^a   Glasgow, B J ^a   Isenberg, S J ^a   George, B L ^a   McDiarmid, S V ^a  

^a JULES STEIN EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ANTERIOR EYE CHAMBER; ARTICLE; CALCULATION; CASE REPORT; CHILD; DIFFERENTIAL DIAGNOSIS; EYE DISEASE; FEMALE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; IRIS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISEASE; MALE; POSTOPERATIVE COMPLICATION; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; UVEITIS;

ADOLESCENT; ANTERIOR CHAMBER; CHILD; CHILD, PRESCHOOL; EYE DISEASES; FEMALE; HEART TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; VISUAL ACUITY;

EID: 0035124511     PISSN: 00039950     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (34)

1. Classification of Epstein-Barr virus-associated posttransplant lymphoproliterative diseases: Implications for understanding their pathogenesis and developing rational treatment strategies
2. Post-transplant lymphoproliferative disorder
3. The diagnosis and treatment of posttransplant lymphoproliferative disorders
4. The pathology of posttransplant lympho-proliferative disorders occurring in the setting of cyclosporine A - Prednisone immunoseppression
5. Development and incidence of cancer following cyclosporine therapy
6. Bilateral iris tumors in an immunosuppressed child
7. Primary ocular posttransplant lymphoproliferative disease
8. Primary Intraocular posttransplantation lymphoproliferative disorder
9. Desordre lymphoproliferatif chorioretinien induit par le virus Epstein-Barr chez un greffe pulmonaire
10. Epstein-Barr virus (EBV)induced polyclonal and monoclonal B-cell lymphoproliferative diseases occurring after renal transplantation: Clinical, pathologic, and virologic findings and implications for therapy
11. Clinical spectrum of lymphoproliferative disorders in renal transplant recipients and evidence for the role of Epstein-Barr virus
12. The Epstein-Barr virus in the pathogen esis of posttransplant lymphoproliferative disorders
13. Epstein-Barr virus, immunodeficiency, and B cell lymphoproliferation
14. SCID mouse model of virus-induced lymphomagenesis of immunodeficient humans
15. Epstein Barr virus (EBV)-associated lymphoproliferative disease in the SCID mouse model: Implications for the pathogenesis of EBV-positive lymphomas in man
16. Malignant lymphoma in cottontop marmosets after inoculation with Epstein-Barr virus
17. The changing pattern of posttransplant malignancies
18. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation
19. Is sequential use of ALG and OKT3 in renal transplants associated with an increased incidence of fulminant posttransplant lymphoproliferative disorder?
20. Orthotopic liver transplantation, Epstein-Barr virus, cyclosporine, and lymphoproliferative disease: A growing concern
21. The frequency of Epstein-Barr virus infection and associated lymphoproliferative syndorme after transplantation and its manifestations in chilren
22. Epstein-Barr virus lymphoproliferative disease associated with acquired immunodeficiency
23. Orbital tumor in a child with posttransplantation lymphoproliferative disorder
24. Prevention and preemptive therapy of posttransplant lymphoproliferative disease in pediatric liver recipients
25. Antiviral prophylaxis and the Epstein Barr virus-related post-transplant lymphoproliferative disorder
26. Incidence of non-Hodgkin lymphoma in kidney and heart transplant recipients
27. Relationship between OKT3 administration, EBV seroconversion and the lymphoproliferative syndrome in pediatric river transplant recipient
28. Increased incidence of lymphoproliferative disorder after immunosuppression with the monoclonal antibody OKT3 in cardiac transplant recipients
29. Posttransplant lymphoproliferative disease in pediatric liver transplantation. Interplay between primary Epstein-Barr virus infection and immunosuppression
30. Lymphoproliferative disease after pediatric liver transplantation
31. Cyclosporin A initially as the only immunosupressant in 34 recipients of cadaveric organs: 32 Kidneys, 2 pancreases, and 2 livers
32. Interactions involving cyclosporine A, interleukin-6, and Epstein-Barr virus lead to the promotion of B-cell lymphoproliferative disease
33. An increased incidence of Epstein-Barr virus infection and lymphoproliferative disorder in young children on FK506 after liver transplantation Transplantation
34. Iris lymphoma in a pediatric cardiac transplant recipient